CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 1 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,496 | -77.5% | 1,397 | -67.2% | 0.00% | -80.0% |
| Q2 2023 | $135,489 | +208344.6% | 4,262 | +59.4% | 0.01% | +150.0% |
| Q1 2023 | $65 | -44.9% | 2,674 | -28.6% | 0.00% | -60.0% |
| Q4 2022 | $118 | -99.9% | 3,747 | -19.4% | 0.01% | +150.0% |
| Q3 2022 | $131,000 | -18.6% | 4,649 | -23.6% | 0.00% | -50.0% |
| Q2 2022 | $161,000 | -16.1% | 6,084 | +10.5% | 0.00% | +100.0% |
| Q1 2022 | $192,000 | +1.6% | 5,506 | -5.6% | 0.00% | -33.3% |
| Q4 2021 | $189,000 | -47.1% | 5,830 | -51.8% | 0.00% | -66.7% |
| Q3 2021 | $357,000 | +792.5% | 12,093 | +678.2% | 0.01% | +800.0% |
| Q2 2021 | $40,000 | +400.0% | 1,554 | +155.2% | 0.00% | – |
| Q1 2021 | $8,000 | +300.0% | 609 | +509.0% | 0.00% | – |
| Q4 2020 | $2,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,912,345 | 41.46% |
| Perceptive Advisors | 6,511,727 | $205,379,869 | 5.77% |
| Finepoint Capital LP | 517,287 | $16,315 | 5.28% |
| Artal Group S.A. | 1,900,000 | $59,926 | 3.34% |
| Affinity Asset Advisors, LLC | 215,000 | $6,781,100 | 2.66% |
| Rock Springs Capital Management LP | 2,506,464 | $79,053,875 | 1.90% |
| Hood River Capital Management LLC | 923,638 | $29,131,543 | 1.06% |
| Logos Global Management LP | 260,000 | $8,200,400 | 0.96% |
| Frazier Life Sciences Management, L.P. | 393,000 | $12,395,220 | 0.77% |
| FEDERATED HERMES, INC. | 2,867,451 | $90,439,405 | 0.25% |